It is estimated that non-Hoxb8 microglia account for 70% of all microglia in the adult brain, significantly outnumbering Hoxb8 microglia, but non-Hoxb8 microglia cannot compensate for the loss of Hoxb8 function in Hoxb8 microglia
By 2026, it's no longer a niche topic whispered about in clinical circles
Garber AJ, Handelsman Y, Grunberger G, Einhorn D, Abrahamson MJ, Barzilay JI, et al
The typical supplemental dose ranges from 30mg to 200mg daily, though some therapeutic protocols use higher amounts under medical supervision
In 2021, Novo Nordisk completed clinical trials studying semaglutide for weight loss, and the results showed sustained, clinically relevant reductions in body weight for overweight and obese participants